Back

Ivabradine for prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: new drugs, new challenges Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Juan Peres De Oliveira

(Brazil)

6 More presentations in this session

Presentation thumbnail
The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis
Mr J. Peres De Oliveira (BR)
Abstract Slides Video
Presentation thumbnail
Influence of the 3-omega fatty acids supplementation on the structure, regulation and vascular function of rats chronically treated with doxorubicin
Ms M. Gaiato Monte (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of TAVI in patients with active cancer: a bridge to success?
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Meta-analysis and predictors of cancer therapy-related right ventricular dysfunction: insights from FAC measurements
Doctor C. Fischer Bacca (Rio do Sul, BR)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: a meta-analysis of efficacy and safety outcomes
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology: new drugs, new challenges

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: heart and vasculature in cardio-oncology
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling
thumbnail
Congress Presentation
SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources